Michael Albrecht Nauck

Head, Clinical Research Diabetes

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Albrecht Nauck is the Head of Clinical Research in Diabetes at Katholisches Klinikum Bochum Sankt Josef-Hospital, Germany. His research primarily focuses on type 2 diabetes, investigating topics such as incretin hormone efficacy, cardiovascular outcomes, and therapeutic comparisons of various diabetes treatments. His recent publications explore critical aspects of diabetes management, including the impact of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter inhibitors.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (1)

Karen Jones

University of South Australia

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Albrecht Nauck

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Changes in the secretion and efficacy of incretin hormones in type 2 diabetes

Comment on "Differences in the efficacy and tolerability of incretin-based diabetes medications"

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics

Getting the measure of the pressure: Optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure

Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes

Pathophysiology of type 2 diabetes Fundamentals to better understand a widespread metabolic disease

Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes

Therapy of Type 2 Diabetes

Treatment of type 2 diabetes

Therapy for type 2 diabetes

Collaborators (1)

Karen Jones

Make your next move.